Risiko endokriner Interventionen bei Trägerinnen einer genetischen Disposition für Brust- und Eierstockkrebs

Die AG „Hormone“ des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs (DK-FBREK) hat Empfehlungen zur Beratung von Patientinnen mit pathogenen Varianten für Brust- und Eierstockkrebs über endokrine Interventionen – wie die Pille, die menopausale Hormontherapie und die ovarielle Stimulation zur Kinderwunschbehandlung – publiziert. Im Folgenden werden Handlungsempfehlungen für den klinischen Alltag, mit dem Schwerpunkt „Familiärer Brustkrebs“, dargelegt – untermauert mit der aktuellen Datenlage.

• Literatur

• 1 Ortmann O, Schueler-Toprak S, Kast K. et al. The risk of endocrine interventions in carriers of a genetic predisposition for breast and gynecologic cancers: recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. J Cancer Res Clin Oncol 2024; 150: 417
• 2 Kuchenbaecker KB, Hopper JL, Barnes DR. et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017; 317: 2402-2416
• 3 Mavaddat N, Barrowdale D, Andrulis IL. et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134-147
• 4 Rhiem K, Auber B, Briest S. et al. Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. Breast Care (Basel) 2022; 17: 199-207
• 5 Parker WH, Feskanich D, Broder MS. et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstet Gynecol 2013; 121: 709-716
• 6 Liu J, Jin X, Liu W. et al. The risk of long-term cardiometabolic disease in women with premature or early menopause: A systematic review and meta-analysis. Front Cardiovasc Med 2023; 10: 1131251
• 7 Challberg J, Ashcroft L, Lalloo F. et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 2011; 105: 22-27
• 8 Rebbeck TR, Friebel T, Wagner T. et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23: 7804-7810
• 9 Kotsopoulos J, Gronwald J, Karlan BY. et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncol 2018; 4: 1059-1065
• 10 Michaelson-Cohen R, Gabizon-Peretz S, Armon S. et al. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. Eur J Cancer 2021; 148: 95-102
• 11 Huber D, Seitz S, Kast K. et al. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review. J Cancer Res Clin Oncol 2021; 147: 2035-2045
• 12 Collaborative Group on Hormonal Factors in Breast C. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727
• 13 Beral V, Doll R. Collaborative Group on Epidemiological Studies of Ovarian C. et al. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008; 371: 303-314
• 14 Schrijver LH, Mooij TM, Pijpe A. et al. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. J Natl Cancer Inst 2022; 114: 540-552
• 15 Cibula D, Zikan M, Dusek L. et al. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 2011; 11: 1197-1207
• 16 Schrijver LH, Olsson H, Phillips KA. et al. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectr 2018; 2: ky023
• 17 Phillips KA, Kotsopoulos J, Domchek SM. et al. Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2. J Clin Oncol 2024;
• 18 Morch LS, Skovlund CW, Hannaford PC. et al. Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med 2017; 377: 2228-2239
• 19 Fitzpatrick D, Pirie K, Reeves G. et al. Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis. PLoS Med 2023; 20: e1004188
• 20 Kim J, Turan V, Oktay K. Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer. J Clin Endocrinol Metab 2016; 101: 1364-1371
• 21 Sergentanis TN, Diamantaras AA, Perlepe C. et al. IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update 2014; 20: 106-123
• 22 van den Belt-Dusebout AW, Spaan M, Lambalk CB. et al. Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer. JAMA 2016; 316: 300-312